Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Jefferies downgraded Tourmaline Bio from "buy" to "hold" with a USD 47.50 price target.
  • Wedbush and Lifesci Capital revised ratings to neutral/market perform with targets near USD 48.00.
  • Consensus rating among analysts remains "Hold" with an average price target of USD 45.61.

Tourmaline Bio, Inc. (NASDAQ: TRML) operates as a clinical biotechnology company focused on developing therapies for immune and inflammatory diseases. Its lead asset, TOUR006, is a human anti-IL-6 monoclonal antibody designed to selectively bind interleukin-6, a proinflammatory cytokine implicated in various autoimmune and inflammatory disorders.

Recent analyst activity has seen Jefferies Financial Group lower its rating from "buy" to "hold," adjusting the price objective from USD 64.00 to USD 47.50. This new target indicates a marginal downside of 0.21% from the stock's previous closing price. In parallel, Wedbush downgraded the stock from "outperform" to "neutral" with a USD 48.00 target, while Lifesci Capital maintained a "market perform" rating at the same target price.

Other analysts continue to maintain a "buy" stance, including Chardan Capital and Guggenheim, which set price targets of USD 70.00 and USD 55.00, respectively. Overall, two analysts have issued a Buy rating, while seven have assigned a Hold rating, leading to a consensus “Hold” recommendation with an average price target of USD 45.61.

Tourmaline Bio’s stock rating reflects mixed opinions from the market, with the majority of analysts favouring a cautious outlook. The company’s focus remains on advancing TOUR006 and other pipeline assets through clinical development, while market participants monitor regulatory progress and clinical trial results closely.